These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26240058)

  • 1. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis.
    Rice LM; Ziemek J; Stratton EA; McLaughlin SR; Padilla CM; Mathes AL; Christmann RB; Stifano G; Browning JL; Whitfield ML; Spiera RF; Gordon JK; Simms RW; Zhang Y; Lafyatis R
    Arthritis Rheumatol; 2015 Nov; 67(11):3004-15. PubMed ID: 26240058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.
    Farina G; Lafyatis D; Lemaire R; Lafyatis R
    Arthritis Rheum; 2010 Feb; 62(2):580-8. PubMed ID: 20112379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.
    Rice LM; Padilla CM; McLaughlin SR; Mathes A; Ziemek J; Goummih S; Nakerakanti S; York M; Farina G; Whitfield ML; Spiera RF; Christmann RB; Gordon JK; Weinberg J; Simms RW; Lafyatis R
    J Clin Invest; 2015 Jul; 125(7):2795-807. PubMed ID: 26098215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.
    Stifano G; Sornasse T; Rice LM; Na L; Chen-Harris H; Khanna D; Jahreis A; Zhang Y; Siegel J; Lafyatis R
    Arthritis Rheumatol; 2018 Jun; 70(6):912-919. PubMed ID: 29858547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.
    Dobrota R; Maurer B; Graf N; Jordan S; Mihai C; Kowal-Bielecka O; Allanore Y; Distler O;
    Ann Rheum Dis; 2016 Oct; 75(10):1743-8. PubMed ID: 27016052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.
    Shand L; Lunt M; Nihtyanova S; Hoseini M; Silman A; Black CM; Denton CP
    Arthritis Rheum; 2007 Jul; 56(7):2422-31. PubMed ID: 17599771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.
    Maurer B; Graf N; Michel BA; Müller-Ladner U; Czirják L; Denton CP; Tyndall A; Metzig C; Lanius V; Khanna D; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1124-31. PubMed ID: 24981642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
    Wannarong T; Muangchan C
    Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study.
    Peytrignet S; Manning J; Wragg E; Moore T; Samaranayaka M; Dinsdale G; Herrick AL
    Scand J Rheumatol; 2019 May; 48(3):230-234. PubMed ID: 30394164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin.
    Rice LM; Mantero JC; Stifano G; Ziemek J; Simms RW; Gordon J; Domsic R; Lafyatis R
    J Invest Dermatol; 2017 Jan; 137(1):62-70. PubMed ID: 27640094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
    Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
    Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time.
    Skaug B; Lyons MA; Swindell WR; Salazar GA; Wu M; Tran TM; Charles J; Vershel CP; Mayes MD; Assassi S
    Ann Rheum Dis; 2022 Apr; 81(4):516-523. PubMed ID: 34937693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan.
    Kuwana M; Hasegawa M; Fukue R; Shirai Y; Ishikawa O; Endo H; Ogawa F; Goto D; Kawaguchi Y; Sato S; Ihn H; Takehara K
    Mod Rheumatol; 2021 Mar; 31(2):386-393. PubMed ID: 32552202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.
    Skaug B; Khanna D; Swindell WR; Hinchcliff ME; Frech TM; Steen VD; Hant FN; Gordon JK; Shah AA; Zhu L; Zheng WJ; Browning JL; Barron AMS; Wu M; Visvanathan S; Baum P; Franks JM; Whitfield ML; Shanmugam VK; Domsic RT; Castelino FV; Bernstein EJ; Wareing N; Lyons MA; Ying J; Charles J; Mayes MD; Assassi S
    Ann Rheum Dis; 2020 Mar; 79(3):379-386. PubMed ID: 31767698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
    Wu W; Jordan S; Graf N; de Oliveira Pena J; Curram J; Allanore Y; Matucci-Cerinic M; Pope JE; Denton CP; Khanna D; Distler O;
    Ann Rheum Dis; 2019 May; 78(5):648-656. PubMed ID: 30852552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker.
    Hesselstrand R; Kassner A; Heinegård D; Saxne T
    Ann Rheum Dis; 2008 Sep; 67(9):1242-8. PubMed ID: 18065498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin involvement in scleroderma--where histological and clinical scores meet.
    Verrecchia F; Laboureau J; Verola O; Roos N; Porcher R; Bruneval P; Ertault M; Tiev K; Michel L; Mauviel A; Farge D
    Rheumatology (Oxford); 2007 May; 46(5):833-41. PubMed ID: 17255134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin score, disease severity, and functional status.
    Gheita TA; Sayed S; Azkalany GS; Abaza N; Hammam N; Eissa AH
    Clin Rheumatol; 2018 Mar; 37(3):757-763. PubMed ID: 29076114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.